Summary.-This report gives the 5-year findings of a double-blind study of longterm cytotoxic chemotherapy as an adjuvant to surgery in patients receiving busulphan or cyclophosphamide for carcinoma of the bronchus compared with a group receiving a placebo. Of 243 patients initially allocated busulphan, 234 cyclophosphamide and 249 placebo, 28%, 27% and 34%0 respectively were alive at 5 years. There were significant associations between mortality from bronchial carcinoma and histological involvement of the resected intrathoracic nodes and the histology of the tumour.
IN 1964 a Medical Research Council
Wvorking Party planned a study to evaluate whether long-term cytotoxic chemotherapy with busulphan or cyclophosphamide, as ani adjuvant to surgery in the treatment of carcinoma of the bronchus, could suppress metastases and prolong survival time, as compared with placebo. The first report (Medical Research Council Working Party, 1971) showed that up to 2 years there was no evidence that either of the cytotoxic agents conferred any benefit. There was, however, a high incidence of hazardous haematological toxicity with busulphan and of side-effects with cyclophosphamide, mostly gastrointestinal.
All the survivors have now been followed up for 5 years and the findings are reported here.
P"LAN AND) CONDUCT OF THE STUDY
The plan and conduct of the study have been described in the earlier report (MRC Working Party, 1971) . In brief, after total resection of the bronchial tumour and removal of all visible intrathoracic growth, the patients were allocated at random to receive tablets of busulphan (the B series), cyclophosphamide (the C series) or indistinguishable placebos (the P series) for 2 years. For the first 10 days patients received 8 tablets in 1 dose daily (1 tablet of busulphan was equivalent to 0 5 mg and 1 of cyclophosphamide to 25 mg). Thereafter for maintenance chemotherapy they received 6 tablets daily in the early stages of the study (the early intake), but due to an unexpectedly high incidence of toxicity from the cytotoxic drugs the maintenance dosages w,ere halved to 3 tablets daily for all 3 regimens (the late intake). The study was conducted doubleblind throughout the 5-year period, neither the patient nor the clinician knowing the agent allocated.
Management of the patients.-The patient's general condition wias reported on by the physician, monthly during the first 3 years and 3-monthly thereafter, and a posteroanterior chest radiograph w%as taken 3-monthly. The haemoglobin estimation, total white cell and platelet counts were undertaken monthly in the first 2 years and * 1'resent ad(dress: Divisioii of Ptulmonary Diseases, Department of Medlicine., Baiaras Hindlut UniversitY. Varanasi-22100.5, Indlia. thereafter only when requested by the physician.
RESULTS
As there were no important differences between patients in the early and late intakes (except in the occurrence of drug toxicity) the amalgamated results are presented. Survival in the 3 series up to 5 years
The survival rates were similar in the 3 series (Table I and Figure) . The fatality from bronchial carcinoma of patients whose resected intrathoracic nodes were histologically involved (Table  III) was higher for all 4 main tumour types than for those whose nodes were not involved, the differences for epidermoid tumours and adenocarcinoma being highly (b) Haematological toxicity. Abnormal blood counts were reported on one or more occasions in 730o of the B compared with 37% of the C and 20% of the P patients (Table IV) . The commonest manifestation on all 3 regimens was thrombocytopenia and the difference between the B patients and each of the other 2 series was highly significant (P < 0 0001) for each of the 4 comparisons. Nineteen (80%) of the B patients developed a pancytopenia compared with only 1 of the C and none of the P patients.
An important feature of the thrombocytopenia in the B series was the length of time for which low platelet counts continued after the drug had been stopped. Thus in 15 (90 %) the condition continued for more than 2 years, in 29 (170%) for 1 to 2 years, in 67 (39%) up to 1 year after the drug was stopped and in 61 (350o) it stopped at or before the time of termination of busulphan. However, it was not unusual for normal counts to occur sporadically among a series of abnormals. In contrast, in only 5 C and 2 P patients did abnormal platelet counts occur after stopping the tablets and in none did the condition continue for longer thain 6 months. In view of reports (Karrer, 1972; Karrer, Pridun and Zwintz, 1973) 
DISCUSSION
This investigation has yielded no evidence that either of the 2 cytotoxic drugs in the dosage schedules studied suppressed or delayed the development of metastases in bronchial carcinoma, or improved survival in a 5-year period of observation of patients who had a total resection of their tumour and all visible intrathoracic growth and had no detectable extrathoracic metastases. There was also no evidence that either of the cytotoxic drugs influenced the survival of any subgroup of patients, identifiable by age, sex, histological involvement of resected intrathoracic nodes or type of tumour. This study investigated 2 different cytotoxic drugs each given alone daily for a long period, a standard practice in the chemotherapy of malignant disease at the time. Since then, however, there has been some evidence that cytotoxic chemotherapy is more effective in bronchial carcinoma if given intermittently in high dosage (Bergsagel, 1971; Karrer, 1972) and if combinations of several drugs are used (Carbone et al., 1970; Alberto, 1973) . Most of these reports have concerned patients with limited disease or who have undergone surgical resection. Laing et al. (1975) however, have reported in patients with inoperable carcinoma of the bronchus that a policy of giving no immediate treatment gave better survival rates and quality of remaining life than single or multiple drug therapy.
There have been varying claims for cyclophosphamide as an adjuvant to radical surgery. Dolton (1970) reported that, given orally for 2 days before and up to 9 days after resection for carcinoma of the bronchus in 114 patients, it did not diminish the incidence of metastases or prolong survival at 2 years when compared with a previous series treated by operation only. Brunner, Marthaler and Muller (1973) found that cyclophosphamide i.v. in intermittent courses over a period of 2 years led to a significantly tncreased recurrence rate and mortality compared with an untreated control group, but Green et al. (1969) , in a controlled study, reported improved survival of patients when the drug was administered i.v. in several courses. These studies were of all cell types but there is some evidence that cyclophosphamide is more active against small-cell tumours (Green et al., 1969; Higgins, 1972; H0st, 1973) . This was not the experience in the present study, nor in Tattersall and Ryall's investigation (1975) in patients treated with radiotherapy plus intermittent combination chemotherapy, including cyclophosphamide.
The patients in the present study were a selected group because all visible growth had been removed at operation, and over half had no histological involvement of the resected intrathoracic nodes. The survival of 30% at 5 years is similar to the survival rates of 25%O to 30%o frequently reported for bronchial carcinoma of all histological types in patients whose growth has been resected (Belcher and Anderson, 1965; Bignall, Martin and Smithers, 1967; Higgins et al., 1969; Pool, 1971) .
It is generally held that the best chance of survival in lung cancer is with a well-differentiated cell type and when complete resection of the growth has been possible. In the patients under study, all of whom had a radical resection, the cell type of the tumour was demonstrated to influence the prognosis only if the intrathoracic nodes were also histologically involved, patients with epidermoid tumours having a better prognosis than those with small-cell tumours (P < 0 05) and those with adenocarcinoma (P < 0 01). In contrast, although patients with histologically uninvolved nodes had a significantly better prognosis than those with involved nodes (P < 0.000 1), the differences in fatality in the various cell types in this group were small, although there was a suggestion that patients with epidermoid tumours fared slightly better.
Several other features previously reported to be of prognostic importance such as age (Belcher and Anderson, 1965; Higgins et al., 1969) , sex (Watson and Schottenfeld, 1968) , type of operation (Bignall et al., 1967; Pool, 1971 ) and site of tumour (Higgins and Beebe, 1967) There was a high incidence ofhazardous toxicity with busulphan, which was prescribed in a dosage which had been selected on the basis of experience in chronic myeloid leukaemia. The drug materially contributed to death in 5 (70 %) of 76 patients in the early intake, and pancytopenia was exceptionally frequent, occurring in 19 (8%) of the 243 patients. A high proportion of the patients had busulphan stopped because of thrombocytopenia; many had low platelet counts for more than 1 year subsequently. In contrast, haematological abnormalities were less frequent with cyclophosphamide and seldom persisted after stopping the drug. Finally, none of the patients on busulphan (or cyclophosphamide) developed radiographic evidence of lung changes which could be ascribed to the drug (Stott et al., 1976) .
All the surviving patients are still being followed up to study whether there is a risk of leukaemia with either cytotoxic agent. 
